Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval.
The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company's Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.
Company Details
- Employees
- 151
- Address
- 450 Lexington Ave,
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- everestmedicines.com
- HQ
- New York, NY
Everest Medicines Questions
Everest Medicines's website is everestmedicines.com
Everest Medicines's LinkedIn profile is https://www.linkedin.com/company/everest-medicines
Everest Medicines has
151 employees.
View email and phone details for 151
employees at Everest Medicines.
Everest Medicines's industry is
Pharmaceutical Manufacturing
Everest Medicines's top competitors are
Gilead Sciences,
Bristol Myers Squibb,
云顶新耀医药科技有限公司,
Msd,
Beigene,
Roche,
Boehringer Ingelheim,
Cbc Group,
Pfizer,
Sanofi.
Everest Medicines's categories are Pharmaceutical Manufacturing
